LEVOFLOXACIN PREVENTS FEBRILE NEUTROPENIA DURING CYTARABINE CONSOLIDATION (IDAC/HIDAC) IN ACUTE MYELOID LEUKEMIA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240401009

Enrollment

Registered

2024-04-01

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We aimed to evaluate the efficacy of levofloxacin for febrile neutropenia prevention following cytarabine containing consolidation chemotherapy (intermediate dose-IDAC or high dose-HIDAC) in newly diagnosed AML patients. AML , febrile neutropenia, levofloxacin

Interventions

all patient received levofloxacin 750 mg once daily for 10 days, beginning on the 5th day after the last dose of cytarabine,patients did not receive levofloxacin prophylaxis

Experimental Drug,No Intervention Drug

levofloxacin,none

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 18-65 years old Newly diagnosed AML S/P IDAC/HIDAC From Jan 2021 to Dec 2023 Accept Informed consent

Exclusion criteria

Exclusion criteria: Rate of hospital admission due to febrile neutropenia Length of hospital stay due to febrile neutropenia Culture-positive bacteremia rate Composite outcome of septic shock rate and infectious-related mortality Side effects of levofloxacin Clostridium difficile-associated disease in 30 days after taking levofloxacin Fluoroquinolone resistance organism

Design outcomes

Primary

Measure	Time frame
Clinically documented Febrile neutropenia 120 days number of patients	—

Secondary

Measure	Time frame
Rate of hospital admission due to febrile neutropenia 120 days days	—

Countries

Thailand

Contacts

Public ContactWarangkana Assawawongsawat

KCMH

prim_as@outlook.com6622564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026